Water-soluble peptide fluorescence material

Abstract

A water-soluble peptide fluorescence material having a structure of formula (I): ##STR00001## In formula (I), n is an integer greater than or equal to 1, R.sub.1 is independently selected from hydrogen or a nitrogen-containing functional group, R.sub.2 is independently selected from hydrogen or alkyl, and A.sub.1 is polymerized by at least one amino acid monomer and having a structure of formula (II): ##STR00002## In formula (II), m is an integer greater than or equal to 1, and R.sub.3 in each of the amino acid monomers of A.sub.1 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl. A.sub.2 is OR.sub.5 or N(R.sub.4).sub.2, and R.sub.4 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, guanidinylalkyl, monoglycosyl, biglycosyl, or oligosaccharyl, and R.sub.5 is hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl.

Claims

1. A method of preparing a water-soluble peptide fluorescence material, the method comprising: grafting a first amino acid monomer to a resin, and an amino group of the first amino acid monomer having a first protective group thereon; wherein the amino group of the first amino acid monomer has a structure of a group A1 connected with a group A2, wherein the group A1 has a structure of formula (1): ##STR00049## in formula (1), wherein m is an integer greater than or equal to 1, R.sub.3 in each of the amino acid monomers of A.sub.1 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl, wherein the group A.sub.2 is OR.sub.5 or N(R.sub.4).sub.2, wherein R.sub.4 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, guanidinylalkyl, monoglycosyl, biglycosyl, or oligosaccharyl, and R.sub.5 is hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl; removing the first protective group from the amino group; using a coupling agent to couple ##STR00050## with the amino group to form the water-soluble peptide fluorescence material, and R.sub.1 being independently selected from the group consisting of pyrrolidine, piperidine, azepane and azocane, R.sub.2 is independently selected from hydrogen or alkyl, and n is an integer greater than or equal to 1; and cleaving the water-soluble peptide fluorescence material from the resin, wherein the water-soluble peptide fluorescence material has a structure of formula (I): ##STR00051##

2. The method of preparing a water-soluble peptide fluorescence material of claim 1, after removing the first protective group, further comprising: using the coupling agent to couple a second amino acid monomer with the amino group of the first amino acid monomer, and an amino group of the second amino acid monomer having a second protective group thereon, wherein the amino group of the second amino acid monomer has a structure of a group A1 connected with a group A2, wherein the group A1 has a structure of formula (1): ##STR00052## in formula (1), wherein m is an integer greater than or equal to 1, R.sub.3 in each of the amino acid monomers of A.sub.1 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl, wherein the group A.sub.2 is OR.sub.5 or N(R.sub.4).sub.2, wherein R.sub.4 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, guanidinylalkyl, monoglycosyl, biglycosyl, or oligosaccharyl, and R.sub.5 is hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl; and removing the second protective group.

3. The method of preparing a water-soluble peptide fluorescence material of claim 1, wherein the coupling agent comprises O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluraniumhexafluorophosphate.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The disclosure can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows:

(2) FIGS. 1A, 1B and 1C are comparative pictures between a water-soluble peptide fluorescence material of the present disclosure and a traditional fluorescence material at the same concentration.

(3) FIG. 2 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material at different pH values.

(4) FIG. 3 illustrates survival rate of PC-3 cells in different concentrations of the water-soluble peptide fluorescence material.

(5) FIG. 4 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-1) in co-solvents having different proportions of water and dimethyl sulfoxide.

(6) FIG. 5 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-10) at different pH values.

(7) FIG. 6 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-14) in co-solvents having different proportions of glycerol and methanol.

(8) FIG. 7 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-21) at different pH values.

(9) FIG. 8 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-22) at different pH values.

(10) FIG. 9 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-23) in co-solvents having different proportions of water and dimethyl sulfoxide.

(11) FIG. 10 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-23) at different pH values.

(12) FIG. 11 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-27) at different pH values.

(13) FIG. 12 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-28) in co-solvents having different proportions of water and dimethyl sulfoxide.

(14) FIG. 13 depicts a ratio of the fluorescence intensity between Experimental Examples 1202 to 1211 and Experimental Example 1201, at the emission wavelength of 400 nm.

(15) FIG. 14 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-28) at different pH values.

(16) FIG. 15 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-30) in co-solvents having different proportions of water and dimethyl sulfoxide.

(17) FIG. 16 depicts a ratio of the fluorescence intensity between Experimental Examples 1502 to 1511 and Experimental Example 1501, at the emission wavelength of 410 nm.

DETAILED DESCRIPTION

(18) The detailed description provided below in connection with the appended drawings is intended as a description of the present examples and is not intended to represent the only forms in which the present example may be constructed or utilized. The description sets forth the functions of the example and the sequence of steps for constructing and operating the example. However, the same or equivalent functions and sequences may be accomplished by different examples. Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.

(19) The present disclosure provides a water-soluble peptide fluorescence material, which has a characteristic of aggregation-induced emission (AlE) by changing a nitrogen heterocycle on naphthalimide, so as to prepare fluorescence dyes having different colors. In addition, an amino acid sequence grafted to the naphthalimide is changed to make the water-soluble peptide fluorescence material develop color in acid, neutral or weak base environment. The water-soluble peptide fluorescence material of the present disclosure has a structure of formula (I):

(20) ##STR00006##

(21) In formula (I), n is an integer greater than or equal to 1, R.sub.1 is independently selected from hydrogen or a nitrogen-containing functional group, and R.sub.2 is independently selected from hydrogen or alkyl. In some embodiments, the nitrogen-containing functional group is glucosamine, nitro group, pyrrolidine, piperidine, azepane or azocane. In some embodiments, R.sub.2 is an alkyl group of 1-16 carbon atoms.

(22) A1 of formula (I) is polymerized by at least one amino acid monomer and having a structure of formula (II):

(23) ##STR00007##

(24) In formula (II), m is an integer greater than or equal to 1, and R.sub.3 in each of the amino acid monomers of A.sub.1 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl. In some embodiments, the amino acid monomers of A.sub.1 are the same. In various embodiments, the amino acid monomers of A.sub.1 are different from each other.

(25) Continuing in formula (I), A.sub.2 thereof has a formula of OR.sub.5 or N(R.sub.4).sub.2. R.sub.4 is independently selected from hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, guanidinylalkyl, monoglycosyl, biglycosyl, or oligosaccharyl, and R.sub.5 is hydrogen, alkyl, aralkyl, alkylthioaalkyl, hydroxyaralky, heteroaralkyl, carboxylalkyl, or guanidinylalkyl. In some embodiments, the monoglycosyl is fructosyl or galactosyl, the biglycosyl is mannosyl, and the oligosaccharyl is oligonucleic acid.

(26) In some embodiments, n is the integer of from 1 to 10, and m is the integer of from 1 to 20.

(27) The water-soluble peptide fluorescence material is designed to illuminate in acid, neutral or weak base environment, and following embodiments give an example illuminating in acid environment. FIGS. 1A, 1B and 1C are comparative pictures between a water-soluble peptide fluorescence material of the present disclosure and a traditional fluorescence material at the same concentration. The water-soluble peptide fluorescence material has a structure of following formula including a peptide sequence Phe-Asp-Gly-Glu-Ala (SEQ ID NO: 5):

(28) ##STR00008##

(29) FIG. 1A uses a traditional, red fluorescence material, Lysotracker (Life Technologies), which is available in the market and used to mark acidic cells in living cells. As shown in FIG. 1A, Lysotracker appears red fluorescence at the acidic cells. Continuing in FIG. 1B to compare with FIG. 1A, FIG. 1B uses the water-soluble peptide fluorescence material of the present disclosure, which is also used to mark acidic cells in living cells. The water-soluble peptide fluorescence material appears green fluorescence at the acidic cells and has a fluorescence intensity greater than that of the red fluorescence of Lysotracker. FIG. 1C is an overlapped picture of FIG. 1A and FIG. 1B, which shows that the water-soluble peptide fluorescence material generates fluorescence at a cellular position substantially the same as Lysotracker. Accordingly, the water-soluble peptide fluorescence material is suitable for a biological fluorescence probe, so as to detect and mark positions of the acidic cells.

(30) At the same concentration, the water-soluble peptide fluorescence material has the greater fluorescence intensity than that of Lysotracker. On this base, a dose of the water-soluble peptide fluorescence material could be decreased to achieve the same fluorescence intensity with the Lysotracker, so as to decrease medical costs and damage to human bodies.

(31) Furthermore, the water-soluble peptide fluorescence material has a characteristic of aggregation-induced emission. The water-soluble peptide fluorescence material is placed in a co-solvent of water and organic solvent, and it is observed that the fluorescence intensity of the co-solvent is increased corresponding to a volume ratio of water. The amino acid of the water-soluble peptide fluorescence material has a hydrogen bond, which causes the characteristic of aggregation-induced emission in water to increase image contrast of cells, and thus has wide range of applications and easily to be operated.

(32) FIG. 2 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material at different pH values. The water-soluble peptide fluorescence material has a structure of following formula including a peptide sequence Phe-Asp-Gly-Glu-Ala (SEQ ID NO: 5):

(33) ##STR00009##

(34) In Experimental Examples 210, 220, 230, 240, 250, 260, 270 and 280, the above water-soluble peptide fluorescence material is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 210 to 230, the water-soluble peptide fluorescence material is respectively placed in environments having the pH value of 10, 9 and 8. As shown in FIG. 2, Experimental Examples 210 to 230 have low fluorescence intensities, so no significant fluorescence marker is shown. Even through the fluorescence intensity of Experimental Example 240 is slightly increased in a neutral environment (pH=7), but the fluorescence intensity thereof is still similar to Experimental Examples 210 to 230, so no significant fluorescence is shown. In addition, the water-soluble peptide fluorescence material of Experimental Example 250 in acidic environment (pH=6), but the fluorescence intensity thereof has no significant change compared to Experimental Examples 210 to 240.

(35) While the pH value is decreased to 5 (Experimental Example 260), the fluorescence intensity of the water-soluble peptide fluorescence material is significantly increased to about 350 fluorescent units, and the emission peak is at about 550 nm to show the green fluorescence as observed in FIG. 1B. Then, the pH value is decreased to 4, and the fluorescence intensity of Experimental Example 270 is increased to about 500 fluorescent units. In Experimental Example 280, the pH value is decreased to 3, and the fluorescence intensity thereof is significantly increased to about 900 fluorescent units. It is worth noting that, the best known fluorescence material has a maximum fluorescence intensity of only about 350 fluorescent units in the acidic environment. Relatively, the water-soluble peptide fluorescence material provided by the present disclosure is able to achieve a fluorescence intensity of 900 fluorescent units, which not only provides obvious marker, but also achieves the same effect of the fluorescence at a low concentration, and thereby reduces the costs. In addition, the fluorescence intensity of Experimental Example 240 (pH=3) is 25.5 times of the fluorescence intensity of Experimental Example 280 (pH=7), which represents that the water-soluble peptide fluorescence material has obvious light-emitting interval and easily to identify and detect positions of the acidic cells.

(36) Continuing in FIG. 3, which illustrates survival rate of PC-3 cell in different concentrations of the water-soluble peptide fluorescence material. The water-soluble peptide fluorescence material has a structure of following formula including a peptide sequence Phe-Asp-Gly-Glu-Ala (SEQ ID NO: 5):

(37) ##STR00010##

(38) As shown in FIG. 3, the PC-3 cell (BCRC-60122, Food Industry Research and Development Institute, FIRDI) has a survival rate of 80% after placing in the water-soluble peptide fluorescence material of 500 M for two days. The above experimental result is much better than a standard of IC50 (50% inhibitory concentration). IC50 represents a concentration of a drug that is required for 50% survival rate of the cells, which means that a certain concentration of a drug is used to detect a cell mortality rate of 50%, and the certain concentration is also referred as 50% inhibitory concentration. Described in different ways, when a ratio of death cells to original cells is 50%, the corresponding concentration is 50% inhibitory concentration. The water-soluble peptide fluorescence material of the present disclosure has low toxicity and excellent compatibility to PC-3 cells, so as to avoid mass mortality of the cells. In addition, HeLa, MCF-7, CTXTAN2, PC12, WSI, 3T3L1 cells are also tested. The water-soluble peptide fluorescence material has excellent compatibility with these cells since the survival rate of these cells are all over 50%.

(39) The water-soluble peptide fluorescence material is prepared by a solid phase peptide synthesis (SPPS), which includes following steps: 1. A first amino acid monomer is grafted to a resin, and an amino group of the first amino acid monomer having a first protective group thereon. 2. The first protective group is removed from the amino group. 3. A coupling agent is used to make

(40) ##STR00011##
couple with the amino group (protective group thereon is removed) of the first amino acid monomer to form the water-soluble peptide fluorescence material, and R.sub.1 is independently selected from hydrogen or a nitrogen-containing functional group. 4. The water-soluble peptide fluorescence material is cleaved from the resin.

(41) In some embodiments, the nitrogen-containing functional group is glucosamine, nitro group, pyrrolidine, piperidine, azepane or azocane.

(42) It is worth noting that a second amino acid monomer the same with or different from the first amino acid monomer is coupled to the amino group of the first amino acid monomer after step 2. The second amino acid monomer has a second protective group, which is removed to expose an amino group of the second amino acid monomer. Then

(43) ##STR00012##
is coupled to the amino group of the second amino acid monomer. As such, amino acid amino acid sequence of the water-soluble peptide fluorescence material could be controlled to develop color at different pH value. Following is embodiments to further describe a method of preparing the water-soluble peptide fluorescence material.

(44) 1. Synthesis of Terminal Luminophore

(45) First, a terminal luminophore of the water-soluble peptide fluorescence material is synthesized by adding acid anhydride, glycine and triethylamine in an ethanol solvent to prepare a mixture, which is refluxed for 6 hours, and the above reaction is traced by thin-layer chromatography (TLC). After the reaction, the mixture is cooled to a room temperature, and most of the ethanol solvent is removed by a rotational vacuum concentrator. Then, a hydrochloric acid having a molar concentration of 1M is slowly added to precipitate a solid. After a suction filtration process, the solid is took out and purified by recrystallization, and a solid product is obtained by filtering. Various reactants of the terminal luminophore and the products obtained from these reactants are listed in Table 1.

(46) TABLE-US-00001 TABLE 1 Synthesis of various terminal luminophores by different acid anhydrides. abbreviation of triethylamine the product acid anhydride glycine (volume, (color, weight, (weight, mol) (weight, mol) mol) yield) 1,8-Naphthalic glycine triethylamine NI anhydride (1.7 g, (3.2 ml, foumula(IV-1) (1.5 g, 7.58 mmol) 22.67 mmol) 22.8 mmol) (white, 1.3278 g, 68.65%) 4-piperidine-1,8- glycine triethylamine PPNI naphthalimide (1.710 g, (3.19 mol, foumula (IV-2) (2.142 g, 7.6 mmol) 22.8 mmol) 22.8 mmol) (yellow, 1.60 g, 66%) 4-pyrrolidino-1,8- glycine triethylamine PRNI naphthalimide (1.125 g, (2.1 ml, foumula (IV-3) (1.335 g, 5 mmol) 15 mmol) 15 mmol) (orange, 0.21 g, 13%) 4-azepanyl-1,8- glycine triethylamine AHNI naphthalimide (0.517 g, (0.97 ml, foumula (IV-4) (0.407 g, 6.9 mmol) 6.9 mmol) (yellow, 0.462 g, 1.38 mmol) 91%) 4-azocanylacetic- glycine triethylamine AONI 1,8-naphthalimide (0.517 g, (0.97 ml, (IV-5) (0.428 g, 6.9 mmol) 6.9 mmol) (yellow, 0.460 g, 1.38 mmol) 91%)

(47) NI has a structure of formula (IV-1):

(48) ##STR00013##

(49) The product of formula (IV-1) is under structure analysis by an nuclear magnetic resonance (.sup.1H NMR), and the NMR spectroscopy is shown below:

(50) .sup.1H NMR (300 MHz, DMSO-d6) =4.78 (s, 2H; CH.sub.2), 7.94 (dd, J (H, H)=7.8, 7.8 Hz, 2H; CH), 8.55 (d, J (H, H)=7.8 Hz, 2H; CH), 8.56 (d, J (H, H)=7.8 Hz, 2H; CH). The structure of formula (IV-1) is referred to NI (1,8-naphthalimide-N-acetic acid) in order to facilitate the subsequent descriptions.

(51) PPNI has a structure of formula (IV-2):

(52) ##STR00014##

(53) The product of formula (IV-2) is under structure analysis by the nuclear magnetic resonance (1H NMR), and the NMR spectroscopy is shown below:

(54) .sup.1H NMR (300 MHz, DMSO-d6): =1.68-1.75 (br, 2H; CH.sub.2), 1.80-1.95 (br, 4H; CH.sub.2), 3.26 (t, J=5.0 Hz, 4H; CH.sub.2), 4.75 (s, 2H; CH.sub.2), 7.36 (d, J=8.1 Hz, 1H; CH), 7.87 (dd, J=7.5, 7.5 Hz, 1H; CH), 8.44 (d, J=8.1 Hz, 1H; CH), 8.51 (d, J=7.5 Hz, 1H; CH), 8.54 (d, J=7.5 Hz, 1H; CH). The structure of formula (IV-2) is referred to PPNI (4-piperidinyl-naphthalimide) in order to facilitate the subsequent descriptions.

(55) PRNI has a structure of formula (IV-3):

(56) ##STR00015##

(57) The product of formula (IV-3) is under structure analysis by an nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR), and the NMR spectroscopy is shown below:

(58) .sup.1H NMR (300 MHz, DMSO-d6): =2.05 (s, 4H; CH.sub.2), 3.79 (s, 4H; CH.sub.2), 4.71 (s, 2H; CH.sub.2), 6.87 (d, J=8.7 Hz, 1H; CH), 7.63 (dd, J=7.6, 7.6 Hz, 1H; CH), 8.23 (d, J=8.7 Hz, 1H; CH), 8.44 (d, J=7.6 Hz, 1H; CH), 8.76 (d, J=7.6 Hz, 1H; CH);

(59) .sup.13C NMR (75 MHz, DMSO-d6): =26.5, 41.8, 53.9, 109.0, 109.4, 121.9, 122.6, 124.1, 131.7, 131.8, 134.1, 150.1, 153.3, 163.3, 164.5, 170.6;

(60) MS [ESI.sup.]: m/z (%): expected value: 324.11, experimental value: 323.1 [M-H].sup.. The structure of formula (IV-3) is referred to PRNI (4-pyrrolidyl-naphthalimide) in order to facilitate the subsequent descriptions.

(61) AHNI has a structure of formula (IV-4):

(62) ##STR00016##

(63) The product of formula (IV-4) is under structure analysis by an nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR), and the NMR spectroscopy is shown below:

(64) .sup.1H NMR (300 MHz, DMSO-d6): =1.60-1.80 (br, 4H; CH.sub.2), 1.80-2.05 (br, 4H; CH.sub.2), 3.61 (t, J=5.25 Hz, 4H; CH), 4.71 (s, 2H; CH.sub.2), 7.19 (d, J=8.4 Hz, 1H; CH), 7.70 (dd, J=7.8, 7.8 Hz, 1H; CH), 8.26 (d, J=8.4 Hz, 1H; CH), 8.42 (d, J=7.8 Hz, 1H; CH), 8.47 (d, J=7.8 Hz, 1H; CH);

(65) .sup.13C NMR (75 MHz, DMSO-d6): =28.2, 28.7, 41.8, 55.6, 112.3, 113.8, 122.5, 124.9, 125.3, 131.0, 131.7, 133.2, 133.4, 157.9, 163.4, 164.3, 170.5;

(66) MS [ESI.sup.]: m/z (%): expected value: 352.14, experimental value: 350.9 [M-H].sup.. The structure of formula (IV-4) is referred to AHNI (4-azacycloheptyl-naphthalimide) in order to facilitate the subsequent descriptions.

(67) AONI has a structure of formula (IV-5):

(68) ##STR00017##

(69) The product of formula (IV-5) is under structure analysis by an nuclear magnetic resonance (1H NMR and .sup.13C NMR), and the NMR spectroscopy is shown below:

(70) .sup.1H NMR (300 MHz, DMSO-d6): =1.55-1.75 (br, 6H; CH.sub.2), 1.75-1.95 (br, 4H; CH.sub.2), 3.68 (t, J=10.5 Hz, 4H; CH), 4.72 (s, 2H; CH.sub.2), 7.26 (d, J=8.7 Hz, 1H; CH), 7.71 (dd, J=8.0, 8.0 Hz, 1H; CH), 8.27 (d, J=8.7 Hz, 1H; CH), 8.4 (d, J=8.0 Hz, 1H; CH), 8.54 (d, J=8.0 Hz, 1H; CH);

(71) .sup.13C NMR (75 MHz, DMSO-d6): =25.3, 27.7, 27.8, 41.8, 54.8, 111.6, 113.3, 122.6, 124.5, 125.1, 131.3, 131.8, 132.7, 133.6, 156.4, 163.3, 164.4, 170.6;

(72) MS [ESI.sup.]: m/z (%): expected value: 366.16, experimental value: 365.0 [M-H].sup.. The structure of formula (IV-5) is referred to AONI (4-azacyclooctyl-naphthalimide) in order to facilitate the subsequent descriptions.

(73) 2-1. Solid Phase Peptide Synthesis (Grafting One Amino Acid)

(74) After the synthesis of the terminal luminophore, a solid phase peptide synthesis (SPPS) is applied to prepare the water-soluble peptide fluorescence material using 2-chlorotrityl chloride resin, amino acid and the terminal luminophore.

(75) The amino acid is grafted to the terminal luminophore by following steps. The 2-chlorotrityl chloride resin (1.2 g, 1 mmol) is swelled in anhydrous dichloromethane (CH.sub.2Cl.sub.2) for 30 min, and a first amino acid having a Fmoc protective group is dissolved in anhydrous N, N-dimethylformamide (DMF) and N, N-diisopropylethylamine (DIEA, 0.83 ml, 5.0 mmol). Then, the first amino acid is reacted with the 2-chlorotrityl chloride resin for 1 hour to graft the first amino acid on the 2-chlorotrityl chloride resin.

(76) After that, piperidine (20% in DMF) is added and reacted for 35 minutes to remove the Fmoc protective group on the first amino acid, and the above step is repeated twice (2 minutes each time). Subsequently, the terminal luminophore, DIEA (0.83 ml, 5.0 mmol) and O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluraniumhexafluorophosphate (HBTU, 0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as a coupling agent to make the terminal luminophore couple to a free amino group (the Fmoc protective group thereon is removed) of the first amino acid.

(77) The reaction mixture is stirred overnight, and then the water-soluble peptide fluorescence material is cleaved from the 2-chlorotrityl chloride resin through treatment of trifluoroacetic acid (90% in deionized water) for 3 hours. The resulting solution is further dried under a stream of air, and diethyl ether is added to precipitate a target product. Then, the precipitate is dried under vacuum to remove residual solvent, and the remained solid product is the water-soluble peptide fluorescence material. Continuing in Table 2, which shows different water-soluble peptide fluorescence materials synthesized from various amino acids and terminal luminophores.

(78) TABLE-US-00002 TABLE 2 Different water-soluble peptide fluorescence materials synthesized from various amino acids and terminal luminophores. terminal structure of the first amino acid luminophore product Embodiment (weight, mol) (weight, mol) (color, weight) Embodiment 1 Fmoc-L-phenylalanine NI III-1 (0.78 g, 2.0 mmol) (0.51 g, 2 mmol) (white solid, 0.14 g) Embodiment 2 Fmoc-O-tert-butyl-L-tyrosine NI III-2 (0.92 g, 2.0 mmol) (0.77 g, 3 mmol) (white solid, 0.14 g) Embodiment 3 Fmoc-L-glycine NI III-3 (0.59 g, 2.0 mmol) (0.77 g, 3 mmol) (white solid, 0.17 g) Embodiment 4 Fmoc-L-phenylalanine PPNI III-4 (0.78 g, 2.0 mmol) (1.02 g, 3 mmol) (white solid, 0.18 g)

(79) The product of Embodiment 1 has a structure of formula (III-1):

(80) ##STR00018##

(81) The NMR spectroscopy of the product in Embodiment 1 is shown below:

(82) .sup.1H NMR (300 MHz, DMSO-d6): =2.90-3.15 (m, 2H, CH.sub.2), 4.40-4.50 (m, 1H, CH), 4.73 (s, 2H, CH.sub.2), 7.20-7.40 (m, 5H, CH), 7.94 (t, 2H, CH), 8.50-8.60 (m, 4H, CH), 8.63 (d, 1H, NH);

(83) .sup.13C NMR (75 MHz, DMSO-d6): =38.1, 43.1, 54.9, 122.9, 127.3, 128.2, 128.4, 129.1, 130.2, 131.8, 132.3, 135.5, 135.7, 138.6, 164.1, 167.4;

(84) MS [ESI.sup.]: m/z (%): expected value: 402.12, experimental value: 401.0 [M-H].sup..

(85) Continuing in FIG. 4, which illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-1) in co-solvents having different proportions of water and dimethyl sulfoxide. In Experimental Example 401, 402, 403, 404, 405, 406, 407, 408, 409, 410 and 411, water respectively has 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100% of a total volume of the co-solvent. As shown in FIG. 4, the water-soluble peptide fluorescence material of formula (III-1) has low fluorescence intensity in co-solvents of Experimental Example 401 to 408. As such, no significant fluorescence marker is shown, so it is difficult to observe apparent fluorescence visually. While a volume ratio of water is increased to 80% (Experimental Example 409) and 90% (Experimental Example 410), the fluorescence intensity is significantly increased to 50 and 100 fluorescent units, and weak fluorescence could be observed. The volume ratio of water is further increased to 100%, and the fluorescence intensity of Experimental Example 411 is sharply increased to about 650 fluorescent units, so as to provide a more obvious fluorescence marker. Given the above, the fluorescence intensity of the water-soluble peptide fluorescence material of formula (III-1) is increased corresponding to the increase of the volume ratio of water, which is also referred as aggregation-induced emission (AlE). In addition, the water-soluble peptide fluorescence material of formula (III-1) has the emission wavelength of about 400 nm, so the observed fluorescence has a color of blue violet.

(86) The product of Embodiment 2 has a structure of formula (III-2):

(87) ##STR00019##

(88) The NMR spectroscopy of the product in Embodiment 2 is shown below:

(89) .sup.1H NMR (300 MHz, DMSO-d6): =2.75-3.10 (m, 2H, CH.sub.2), 4.30-4.45 (m, 1H, CH), 4.73 (s, 1H, CH.sub.2), 6.72 (d, J=7.8 Hz, 2H, CH), 7.06 (d, J=7.8 Hz, 2H, CH), 7.92 (t, J=7.65 Hz, 2H, CH), 8.40-8.70 (m, 5H, CH, NH), 9.10-9.40 (br, 1H, OH);

(90) .sup.13C NMR (75 MHz, DMSO-d6): =37.1, 43.0, 55.0, 116.0, 122.8, 128.2, 128.3, 128.4, 131.1, 131.8, 132.3, 135.5, 156.9, 164.1, 167.5, 173.8;

(91) MS [ESI.sup.]: m/z (%): expected value: 418.12, experimental value: 417.1 [M-H].sup..

(92) The product of Embodiment 3 has a structure of formula (III-3):

(93) ##STR00020##

(94) The NMR spectroscopy of the product in Embodiment 3 is shown below:

(95) .sup.1H NMR (300 MHz, DMSO-d6): =3.83 (d, J=5.7 Hz, 2H, CH.sub.2), 4.76 (s, 2H, CH.sub.2), 7.94 (t, J=10.4 Hz, 2H, CH), 8.50-8.65 (m, 5H, CH, NH);

(96) .sup.13C NMR (75 MHz, DMSO-d6): =41.6, 43.1, 122.9, 128.2, 128.5, 131.8, 132.3, 135.5, 164.2, 168.0, 172.0;

(97) MS [ESI.sup.]: m/z (%): expected value: 312.07, experimental value: 310.90 [M-H].sup..

(98) The product of Embodiment 4 has a structure of formula (III-4):

(99) ##STR00021##

(100) The NMR spectroscopy of the product in Embodiment 3 is shown below:

(101) .sup.1H NMR (300 MHz, DMSO-d6): =1.60-1.80 (m, 2H; CH.sub.2), 1.80-1.95 (m, 4H; CH.sub.2), 2.90-3.15 (m, 2H; CH.sub.2), 3.15-3.30 (m, 4H; CH.sub.2), 4.40-4.55 (m, 1H; CH), 4.699 (s, 2H; CH.sub.2), 7.20-7.40 (m, 5H; CH), 7.84 (t, J=7.95 Hz, 1H; CH), 8.35-8.55 (m, 3H; CH), 8.61 (d, J=7.8 Hz, 1H, CH);

(102) .sup.13C NMR (75 MHz, DMSO-d6): =24.8, 26.6, 37.8, 42.8, 54.6, 54.9, 115.8, 115.9, 123.3, 126.4, 126.8, 127.4, 129.1, 130.16, 130.24, 131.6, 131.7, 133.3, 138.3, 157.8, 163.7, 164.3, 167.7, 173.6;

(103) MS [ESI.sup.]: m/z (%): expected value: 485.53, experimental value: 484.1 [M-H].sup..

(104) 2-2. Solid Phase Peptide Synthesis (Grafting Two Amino Acids)

(105) Embodiments of grafting two amino acids is begun with swelling 2-chlorotrityl chloride resin (1.2 g, 1 mmol) in anhydrous dichloromethane (CH.sub.2Cl.sub.2) for 30 min, and a first amino acid having a Fmoc protective group is dissolved in anhydrous DMF and DIEA (0.83 ml, 5.0 mmol). Then, the first amino acid is reacted with the 2-chlorotrityl chloride resin for 1 hour to graft the first amino acid on the 2-chlorotrityl chloride resin. After that, piperidine (20% in DMF) is added and reacted for 35 minutes to remove the Fmoc protective group on the first amino acid, and the above step is repeated twice (2 minutes each time). Subsequently, a second amino acid having a Fmoc protective group, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as a coupling agent to make the second amino acid couple to a free amino group (the Fmoc protective group thereon is removed) of the first amino acid.

(106) Then, piperidine (20% in DMF) is again added and reacted for 20 minutes, and the above step is repeated twice (2 minutes each time) to remove Fmoc protective group on the second amino acid. Subsequently, the terminal luminophore, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as the coupling agent to make the terminal luminophore couple to a free amino group (the Fmoc protective group thereon is removed) of the second amino acid.

(107) The reaction mixture is stirred overnight, and then the water-soluble peptide fluorescence material is cleaved from the 2-chlorotrityl chloride resin through treatment of trifluoroacetic acid (90% in deionized water) for 3 hours.

(108) The resulting solution is further dried under a stream of air, and diethyl ether is added to precipitate a target product. Then, the precipitate is dried under vacuum to remove residual solvent, and the remained solid product is the water-soluble peptide fluorescence material, which is under structure analysis by a nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR). Continuing in Table 3, which shows different water-soluble peptide fluorescence materials synthesized from two amino acids and various terminal luminophores.

(109) TABLE-US-00003 TABLE 3 Different water-soluble peptide fluorescence materials synthesized from two amino acids and various terminal luminophores. structure terminal of the luminophore product first amino acid second amino acid (weight, (color, Embodiment (weight, mol) (weight, mol) mol) weight) Embodiment 5 Fmoc-L- Fmoc-L- NI III-5 glycine glycine (0.51 g, (white (0.59 g, (0.59 g, 2.0 mmol) 2.0 mmol) solid, 2.0 mmol) 0.35 g) Embodiment 6 Fmoc-L- Fmoc-L- NI III-6 phenylalanine phenylalanine (1.53 g, (white (1.16 g, (1.55 g, 4.0 mmol) 6.0 mmol) solid, 3.0 mmol) 0.35 g) Embodiment 7 Fmoc-L- Fmoc-L- NI III-7 phenylalanine tyrosine (1.53 g, (white (1.16 g, 3.0 mmol)) (1.84 g, 4.0 mmol) 6.0 mmol) solid, 1.06 g) Embodiment 8 Fmoc-L- Fmoc-L- NI III-8 tyrosine phenylalanine (1.53 g, (white (1.38 g, 3.0 mmol)) (1.55 g, 4.0 mmol) 6.0 mmol) solid, 1.15 g) Embodiment 9 Fmoc-L- Fmoc-L- NI III-9 tyrosine tyrosine (0.51 g, (pale (0.919 g, 2.0 mmol)) (0.919 g, 2.0 mmol) 2.0 mmol) yellow solid, 0.32 g) Embodiment Fmoc-L- Fmoc-L- NI III-10 10 phenylalanine glycine (1.53 g, (white (1.16 g, (1.19 g, 4.0 mmol) 6.0 mmol) solid, 3.0 mmol) 0.48 g) Embodiment Fmoc-L- Fmoc-L- NI III-11 11 glycine phenylalanine (1.53 g, (white (0.89 g, (1.55 g, 4.0 mmol) 6.0 mmol) solid, 3.0 mmol) 0.38 g) Embodiment Fmoc-L- Fmoc-O-tert- NI III-12 12 glycine butyl-L-tyrosine (0.35 g, (white (0.4 g, (0.61 g, 1.3 mmol) 1.3 mmol) solid, 1.3 mmol) 0.22 g) Embodiment Fmoc-O-tert- Fmoc-L- NI III-13 13 butyl-L-tyrosine glycine (0.77 g, (white (0.92 g, (0.6 g, 2.0 mmol) 3.0 mmol) solid, 2.0 mmol) 0.18 g) Embodiment Fmoc-L- Fmoc-L- PPNI III-14 14 phenylalanine phenylalanine (0.51 g, (yellow (0.58 g, (0.58 g, 1.5 mmol) 1.5 mmol) solid, 1.5 mmol) 0.515 g) Embodiment Fmoc-L- Fmoc-L- PPNI III-15 15 phenylalanine tyrosine (0.51 g, (yellow (0.58 g, (0.69 g, 1.5 mmol) 1.5 mmol) solid, 1.5 mmol) 0.534 g) Embodiment Fmoc-L- Fmoc-L- PPNI III-16 16 aspartic acid aspartic acid (0.677 g, (dark (0.62 g, (0.62 g, 1.5 mmol) 2.0 mmol) brown 1.5 mmol) solid, 0.376 g) Embodiment Fmoc-L- Fmoc-L-phenylalanine PPNI III-17 17 aspartic acid (0.58 g, 1.5 mmol) (0.677 g, (yellow (0.62 g, 2.0 mmol) solid, 1.5 mmol) 0.554 g) Embodiment Fmoc-L- Fmoc-L- PRNI III-18 18 phenylalanine phenylalanine (0.486 g, (orange (0.58 g, (0.58 g, 1.5 mmol) 1.5 mmol) solid, 1.5 mmol) 0.434 g) Embodiment Fmoc-L- Fmoc-L- AHNI III-19 19 phenylalanine phenylalanine (0.528 g, (yellow (0.58 g, (0.58 g, 1.5 mmol) 1.5 mmol) solid, 1.5 mmol) 0.611 g) Embodiment Fmoc-L- Fmoc-L- AONI III-20 20 phenylalanine phenylalanine (0.366 g, (yellow (0.29 g, (0.29 g, 0.75 mmol) 1 mmol) solid, 0.75 mmol) 0.248 g) Embodiment Fmoc-L- Fmoc-L- PPNI III-21 21 glutamic acid phenylalanine (0.507 g, (yellow (0.425 g, (0.387 g, 1.0 mmol) 1.50 mmol) solid, 1.0 mmol) 0.230 g)

(110) The product of Embodiment 5 has a structure of formula (III-5):

(111) ##STR00022##

(112) The NMR spectroscopy of the product in Embodiment 5 is shown below:

(113) .sup.1H NMR (300 MHz, DMSO-d6): =3.75-3.85 (m, 4H; CH.sub.2), 4.783 (s, 1H; CH.sub.2), 7.94 (t, J=7.8 Hz, 2H; CH), 8.24 (t, J=5.7 Hz, 1H; NH), 8.50-8.65 (m, 5H; CH, NH);

(114) .sup.13C NMR (75 MHz, DMSO-d6): =41.5, 42.7, 43.3, 122.9, 128.3, 131.8, 135.5, 164.3, 168.1, 170.0, 172.1;

(115) MS [ESI.sup.]: m/z (%): expected value: 369.10, experimental value: 367.9 [M-H].sup..

(116) The product of Embodiment 6 has a structure of formula (III-6):

(117) ##STR00023##

(118) The NMR spectroscopy of the product in Embodiment 6 is shown below:

(119) .sup.1H NMR (300 MHz, DMSO-d6): =2.75-3.15 (m, 4H; CH.sub.2), 4.40-4.50 (m, 1H; CH), 4.55-4.65 (m, 1H; CH), 4.688 (s, 2H; CH.sub.2), 7.20-7.35 (m, 10H; CH), 7.90-8.00 (t, J=7.8 Hz, 2H; CH), 8.38 (d, J=8.1 Hz, 1H; NH), 8.48 (d, J=8.4 Hz, 1H; NH), 8.54 (d, J=7.5 Hz, 4H; CH);

(120) .sup.13C NMR (75 MHz, DMSO-d6): =37.7, 38.5, 43.1, 54.6, 122.8, 127.1, 127.4, 128.2, 128.4, 128.9, 129.1, 130.0, 130.2, 131.8, 132.3, 135.4, 138.3, 138.5, 164.1, 167.3, 171.8, 173.6;

(121) MS [ESI.sup.]: m/z (%): expected value: 549.19, experimental value: 548.1 [M-H].sup..

(122) The product of Embodiment 7 has a structure of formula (III-7):

(123) ##STR00024##

(124) The NMR spectroscopy of the product in Embodiment 7 is shown below:

(125) .sup.1H NMR (300 MHz, DMSO-d6): =2.60-3.15 (m, 4H; CH.sub.2), 4.40-4.55 (m, 2H; CH), 4.693 (s, 2H; CH.sub.2), 6.68 (d, J=8.1 Hz, 2H; CH), 7.06 (d, J=8.4 Hz, 2H; CH), 7.15-7.40 (m, 5H; CH), 7.3 (t, J=7.65 Hz, 2H; CH), 8.33 (d, J=7.5 Hz, 1H; NH), 8.42 (d, J=8.4 Hz, 1H; NH), 8.53 (d, J=8.1 Hz, 4H; CH);

(126) .sup.13C NMR (75 MHz, DMSO-d6): =37.7, 43.1, 54.5, 55.0, 115.8, 122.9, 127.4, 128.2, 128.4, 128.6, 129.2, 130.1, 131.1, 131.8, 132.3, 135.5, 138.4, 156.7, 164.1, 167.3, 171.9, 173.6;

(127) MS [ESI.sup.]: m/z (%): expected value: 565.18, experimental value: 564.22 [M-H].sup..

(128) The product of Embodiment 8 has a structure of formula (III-8):

(129) ##STR00025##

(130) The NMR spectroscopy of the product in Embodiment 8 is shown below:

(131) .sup.1H NMR (300 MHz, DMSO-d6): =2.75-3.10 (m, 4H; CH.sub.2), 4.35-4.45 (m, 1H; CH), 4.55-4.65 (m, 1H; CH), 4.694 (s, 2H; CH.sub.2), 6.70 (d, J=8.4 Hz, 2H; CH), 7.06 (d, J=8.4 Hz, 2H; CH), 7.20-7.35 (m, 5H; CH), 7.92 (t, J=7.65 Hz, 2H; CH), 8.29 (d, J=7.5 Hz, 1H; NH), 8.45-8.55 (m, 5H; CH, NH);

(132) .sup.13C NMR (75 MHz, DMSO-d6): =40.0, 38.5, 43.1, 54.6, 54.9, 116.0, 122.8, 127.1, 128.2, 128.3, 128.4, 128.9, 130.2, 131.0, 131.8, 132.3, 135.5, 138.6, 156.9, 164.1, 167.4, 171.8, 173.7;

(133) MS [ESI.sup.]: m/z (%): expected value: 565.18, experimental value: 564.2 [M-H].sup..

(134) The product of Embodiment 9 has a structure of formula (III-9):

(135) ##STR00026##

(136) The NMR spectroscopy of the product in Embodiment 9 is shown below:

(137) .sup.1H NMR (300 MHz, DMSO-d6): =2.60-3.15 (m, 4H; CH.sub.2), 4.30-4.40 (m, 1H; CH), 4.40-4.55 (m, 1H; CH), 2.70-2.90 (m, 1H; CH.sub.2), 4.697 (s, 2H; CH.sub.2), 6.60-6.75 (m, 4H; CH), 7.00-7.15 (m, 4H; CH), 7.94 (t, J=7.8 Hz, 2H; CH), 8.21 (d, J=6.9 Hz, 1H; NH), 8.43 (d, J=8.4 Hz, 1H; NH), 8.54 (d, J=7.8 Hz, 4H; CH);

(138) .sup.13C NMR (75 MHz, DMSO-d6): =37.0, 37.7, 43.2, 55.0, 115.8, 116.0, 122.9, 128.2, 128.4, 128.7, 131.0, 131.2, 131.8, 132.3, 135.5, 156.7, 156.9, 164.2, 167.3, 171.9, 173.8;

(139) MS [ESI.sup.]: m/z (%): expected value: 581.1, experimental value: 580.5 [M-H].sup..

(140) The product of Embodiment 10 has a structure of formula (III-10):

(141) ##STR00027##

(142) The NMR spectroscopy of the product in Embodiment 10 is shown below:

(143) .sup.1H NMR (300 MHz, DMSO-d6): =2.85-3.00 (m, 1H; CH.sub.2), 3.00-3.15 (m, 1H; CH.sub.2), 3.65-3.90 (m, 2H; CH.sub.2), 4.35-4.55 (m, 1H; CH), 4.70-4.80 (m, 2H; CH.sub.2), 7.20-7.35 (m, 5H; CH), 7.94 (t, J=7.65 Hz, 1H; CH), 8.20 (d, J=8.4 Hz, 1H; NH), 8.50-8.60 (m, 5H; CH, NH);

(144) .sup.13C NMR (75 MHz, DMSO-d6): =37.9, 43.3, 54.5, 122.9, 127.4, 128.2, 128.5, 129.2, 130.1, 131.8, 132.3, 135.5, 138.4, 164.3, 168.0, 169.5, 173.7;

(145) MS [ESI.sup.]: m/z (%): expected value: 459.14, experimental value: 458.4 [M-H].sup..

(146) Continuing in FIG. 5, which illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-10) at different pH values. In Experimental Examples 510, 520, 530, 540, 550, 560, 570 and 580, the water-soluble peptide fluorescence material of formula (III-10) is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 510 to 560, the water-soluble peptide fluorescence material is placed in environments having the pH value of 10 to 5, and two emission peaks are shown in FIG. 5. One emission peak is at about 400 nm, and the other emission peak is at about 500 nm, so the observed fluorescence is mixed light of green light and purple light. Then, the pH value is further decrease to 4 (Experimental Example 570) and 3 (Experimental Example 580), and only the emission peak at about 400 nm is remained, so the observed fluorescence has a color of purple in Experimental Examples 570 and 580. Therefore, the water-soluble peptide fluorescence material of formula (III-10) is able to detect and mark locations of acidic cells by change of the color.

(147) The product of Embodiment 11 has a structure of formula (III-11):

(148) ##STR00028##

(149) The NMR spectroscopy of the product in Embodiment 11 is shown below:

(150) .sup.1H NMR (300 MHz, DMSO-d6): =2.75-2.90 (m, 1H; CH.sub.2), 3.00-3.10 (m, 1H; CH.sub.2), 3.80-3.90 (m, 2H; CH.sub.2), 4.50-4.65 (m, 1H; CH), 4.65-4.75 (m, 2H; CH.sub.2), 7.20-7.35 (m, 5H; CH), 7.94 (t, J=7.8 Hz, 2H; CH), 8.46 (t, J=5.85 Hz, 1H; NH), 8.54 (d, J=7.8 Hz, 4H; CH), 8.60 (d, J=8.1 Hz, 1H; NH);

(151) .sup.13C NMR (75 MHz, DMSO-d6): =38.8, 41.6, 43.1, 54.8, 122.8, 127.2, 128.2, 128.3, 129.0, 130.2, 131.8, 132.2, 135.4, 138.7, 164.1, 167.5, 172.0, 172.3;

(152) MS [ESI.sup.]: m/z (%): expected value: 459.14, experimental value: 458.1 [M-H].sup..

(153) The product of Embodiment 12 has a structure of formula (III-12):

(154) ##STR00029##

(155) The NMR spectroscopy of the product in Embodiment 12 is shown below:

(156) .sup.1H NMR (300 MHz, DMSO-d6): =2.65-2.80 (m, 1H; CH.sub.2), 2.90-3.00 (m, 1H; CH.sub.2), 3.75-3.85 (m, 2H; CH.sub.2), 4.40-4.55 (m, 1H; CH.sub.2), 4.713 (s, 2H; CH.sub.2), 6.69 (d, J=8.1 Hz, 2H; CH), 7.08 (d, J=8.1 Hz, 2H; CH), 7.92 (t, J=7.8 Hz, 2H; CH), 8.4 (d, J=5.4 Hz, 1H; NH), 8.52 (d, J=7.2 Hz, 4H; CH);

(157) .sup.13C NMR (75 MHz, DMSO-d6): =38.0, 43.2, 55.2, 115.8, 122.9, 128.2, 128.4, 128.7, 131.1, 131.8, 132.3, 135.5, 156.7, 164.2, 167.4, 172.1, 172.4;

(158) MS [ESI.sup.]: m/z (%): expected value: 475.14, experimental value: 474.0 [M-H].sup..

(159) The product of Embodiment 13 has a structure of formula (III-13):

(160) ##STR00030##

(161) The NMR spectroscopy of the product in Embodiment 13 is shown below:

(162) .sup.1H NMR (300 MHz, DMSO-d6): =2.75-2.85 (m, 1H; CH.sub.2), 2.90-3.05 (m, 1H; CH.sub.2), 3.65-3.90 (m, 2H; CH.sub.2), 4.30-4.45 (m, 1H; CH), 4.76 (d, J=3.0 Hz, 2H; CH.sub.2), 6.68 (d, J=8.1 Hz, 2H; CH), 7.04 (d, J=8.4 Hz, 2H; CH), 7.94 (t, J=7.8 Hz, 2H; CH), 8.10 (d, J=7.8 Hz, 1H; NH), 8.50-8.65 (m, 4H; CH);

(163) .sup.13C NMR (75 MHz, DMSO-d6): =37.1, 42.6, 43.3, 54.8, 116.0, 122.9, 128.2, 128.3, 128.36, 128.43, 131.0, 131.8, 132.0, 132.3, 135.5, 135.8, 156.9, 164.0, 164.3, 168.0, 169.4, 170.3, 173.8;

(164) MS [ESI.sup.]: m/z (%): expected value: 475.14, experimental value: 474.0 [M-H].sup..

(165) The product of Embodiment 14 has a structure of formula (III-14):

(166) ##STR00031##

(167) The NMR spectroscopy of the product in Embodiment 14 is shown below:

(168) .sup.1H NMR (300 MHz, DMSO-d6): =1.60-1.80 (br, 2H; CH.sub.2), 1.80-1.95 (br, 4H; CH.sub.2), 2.70-3.20 (m, 4H, CH.sub.2), 3.23 (s, 4H; CH.sub.2), 4.40-4.55 (m, 1H; CH), 4.55-4.75 (m, 2H; CH, OH.sub.2), 7.15-7.45 (m, 11H; CH), 7.82 (dd, J=6.9, 6.9 Hz, 1H; CH), 8.35-8.60 (m, 5H; CH, NH);

(169) .sup.13C NMR (75 MHz, DMSO-d6): =24.8, 26.7, 37.7, 38.5, 43.0, 46.2, 54.5, 54.9, 111.5, 115.75, 115.85, 123.3, 126.4, 126.8, 127.2, 127.4, 128.9, 129.2, 130.1, 130.3, 131.6, 133.3, 138.3, 138.6, 157.8, 163.7, 164.3, 167.5, 171.9, 173.6;

(170) MS [ESI.sup.]: m/z (%): expected value: 632.26, experimental value: 631.1 [M-H].sup..

(171) Continuing in FIG. 6, which illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-14) in co-solvents having different proportions of glycerol and methanol. In Experimental Example 601, 602, 603, 604, 605, 606, 607, 608, 609 and 610, methanol respectively has 0, 10, 20, 30, 40, 50, 60, 70, 80 and 90% of a total volume of the co-solvent. As shown in FIG. 6, the water-soluble peptide fluorescence material of formula (III-14) has largest fluorescence intensity in Experimental Example 610, so as to provide a more obvious fluorescence marker. Given the above, the fluorescence intensity of the water-soluble peptide fluorescence material of formula (III-14) is increased corresponding to the increase of the volume ratio of methanol, so the water-soluble peptide fluorescence material of formula (III-14) also has a phenomenon of aggregation-induced emission (AlE) in methanol. In addition, the water-soluble peptide fluorescence material of formula (III-14) has the emission wavelength of about 550 nm, so the observed fluorescence has a color of green.

(172) The product of Embodiment 15 has a structure of formula (III-15):

(173) ##STR00032##

(174) The NMR spectroscopy of the product in Embodiment 15 is shown below:

(175) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.80 (br, 2H; CH.sub.2), 1.80-2.00 (br, 4H; CH.sub.2), 2.60-3.15 (m, 4H; CH.sub.2), 3.20-3.30 (br, 4H; CH.sub.2), 4.40-4.60 (m, 2H; CH), 4.66 (s, 2H; CH.sub.2), 6.67 (d, J=8.4 Hz, 2H; CH), 7.06 (d, J=8.4 Hz, 2H; CH), 7.15-7.35 (m, 5H; CH), 7.37 (d, J=8.1, 1H; CH), 7.86 (dd, J=7.5, 8.4, 1H; CH), 8.30-8.55 (m, 5H; CH, NH), 9.20 (s, 1H; OH);

(176) .sup.13C NMR (75 MHz, DMSO-d6): =23.9, 25.7, 36.8, 42.0, 53.6, 54.0, 105.6, 114.8, 115.0, 122.4, 125.5, 125.9, 126.4, 127.7, 128.2, 129.1, 129.3, 130.2, 130.7, 132.4, 137.4, 155.7, 156.9, 162.8, 163.4, 166.5, 171.0, 172.7;

(177) MS [ESI.sup.]: m/z (%): expected value: 648.26, experimental value: 647.1 [M-H].sup..

(178) The product of Embodiment 16 has a structure of formula (III-16):

(179) ##STR00033##

(180) The NMR spectroscopy of the product in Embodiment 16 is shown below:

(181) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.80-1.95 (br, 4H; CH.sub.2), 2.60-2.80 (m, Hz, 4H; CH.sub.2), 3.20-3.35 (br, 4H; CH.sub.2), 4.55-4.65 (m, 1H; CH), 4.65-4.75 (m, 3H; CH.sub.2), 7.37 (d, J=8.1 Hz 1H; CH), 7.86 (t, J=7.8 Hz, 1H; CH), 8.11 (d, J=8.1 Hz, 1H; NH), 8.42 (d, J=8.1 Hz, 1H; CH), 8.49 (t, J=8.4 Hz, 2H; CH), 8.62 (d, J=7.8 Hz, 1H; NH);

(182) .sup.13C NMR (75 MHz, DMSO-d6): =23.9, 25.8, 36.0, 36.4, 42.2, 48.7, 49.4, 54.0, 114.8, 114.9, 122.4, 125.5, 125.8, 129.4, 130.8, 130.9, 132.5, 157.0, 163.0, 163.5, 167.1, 170.4, 171.6, 171.7, 172.2;

(183) MS [ESI.sup.]: m/z (%): expected value: 568.18, experimental value: 567.0 [M-H].sup..

(184) The product of Embodiment 17 has a structure of formula (III-17):

(185) ##STR00034##

(186) The NMR spectroscopy of the product in Embodiment 17 is shown below:

(187) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.80-1.90 (br, 4H; CH.sub.2), 2.55-3.10 (m, 4H; CH.sub.2), 3.20-3.30 (br, 4H; CH.sub.2), 4.55-4.65 (m, 2H; CH), 4.67 (s, 2H; CH.sub.2), 7.20-7.25 (m, 1H; CH), 7.25-7.35 (m, J=6.0 Hz, 4H; CH), 7.36 (d, J=8.1 Hz, 1H; CH), 7.86 (t, J=7.95 Hz, 1H; CH), 8.41 (d, J=8.4 Hz, 1H; CH), 8.48 (t, J=7.2 Hz, 4H; CH);

(188) .sup.13C NMR (75 MHz, DMSO-d6): =23.9, 25.7, 36.0, 37.8, 42.0, 48.7, 53.7, 54.0, 114.8, 114.9, 122.4, 125.5, 125.9, 126.3, 128.0, 129.3, 129.4, 130.7, 130.8, 132.4, 137.6, 156.9, 162.8, 163.4, 166.6, 170.9, 171.6, 172.3;

(189) MS [ESI.sup.]: m/z (%): expected value: 600.22, experimental value: 599.0 [M-H].sup..

(190) The product of Embodiment 18 has a structure of formula (III-18):

(191) ##STR00035##

(192) The NMR spectroscopy of the product in Embodiment 18 is shown below:

(193) .sup.1H NMR (300 MHz, DMSO-d6): =1.95-2.10 (br, 4H; CH.sub.2), 2.75-3.20 (m, 4H; CH.sub.2), 3.70-3.90 (br, 4H; CH.sub.2), 4.40-4.55 (m, 1H; CH), 4.55-4.80 (m, 3H; CH, CH.sub.2), 6.89 (d, J=7.8 Hz, 1H; CH), 7.15-7.45 (m, 10H; CH), 7.63 (dd, J=8.0, 8.0 Hz, 1H; CH), 8.23 (d, J=8.0 Hz, 1H; CH), 8.35-8.50 (m, 4H; CH, NH), 8.76 (d, J=8.0 Hz, 1H; CH);

(194) .sup.13C NMR (75 MHz, DMSO-d6): =26.5, 37.7, 38.5, 42.8, 53.8, 54.6, 109.4, 109.5, 122.3, 122.7, 124.1, 127.2, 127.4, 129.0, 129.2, 130.1, 130.3, 131.6, 133.7, 133.9, 138.3, 138.6, 151.4, 153.2, 163.5, 164.6, 167.8, 171.9, 173.6;

(195) MS [ESI.sup.]: m/z (%): expected value: 618.25, experimental value: 617.1 [M-H].sup..

(196) The product of Embodiment 19 has a structure of formula (III-19):

(197) ##STR00036##

(198) The NMR spectroscopy of the product in Embodiment 19 is shown below:

(199) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.80 (br, 4H; CH.sub.2), 1.80-2.00 (br, 4H; CH.sub.2), 2.70-3.20 (m, 4H; CH.sub.2), 3.60-3.75 (br, 4H; CH), 4.40-4.55 (m, 1H; CH), 4.55-4.65 (br, 1H; CH), 4.66 (s, 2H; CH.sub.2), 7.20-7.40 (m, 11H; CH), 7.77 (dd, J=7.5, 8.4 Hz, 1H; CH), 8.30-8.50 (m, 4H; NH, CH), 8.56 (d, J=8.4 Hz, 1H; CH);

(200) .sup.13C NMR (75 MHz, DMSO-d6): =27.1, 28.2, 28.7, 37.7, 38.5, 54.5, 55.7, 58.8, 106.5, 113.0, 114.0, 123.0, 125.1, 127.2, 127.4, 128.9, 129.2, 130.1, 130.3, 131.6, 133.3, 138.3, 138.6, 157.9, 161.8, 163.6, 164.5, 167.6, 167.8, 171.9, 173.6;

(201) MS [ESI.sup.]: m/z (%): expected value: 646.28, experimental value: 645.1 [M-H].sup..

(202) The product of Embodiment 20 has a structure of formula (III-20):

(203) ##STR00037##

(204) The NMR spectroscopy of the product in Embodiment 20 is shown below:

(205) .sup.1H NMR (300 MHz, DMSO-d6): =1.60-1.80 (br, 6H; CH.sub.2), 1.80-2.00 (br, 4H; CH.sub.2), 2.70-3.20 (m, 4H; CH.sub.2), 3.74 (s, 4H; CH), 4.40-4.50 (m, 1H; CH), 4.50-4.70 (m, 3H; CH, CH.sub.2), 7.15-7.45 (m, 11H; CH), 7.65-7.85 (br, 1H; CH), 8.31 (d, J=8.7 Hz, 1H; CH), 8.35-8.55 (m, 3H; CH, NH), 8.61 (d, J=7.5 Hz, 1H; CH);

(206) .sup.13C NMR (75 MHz, DMSO-d6): =25.3, 27.7, 27.8, 37.7, 38.5, 42.8, 54.5, 54.8, 73.0, 112.3, 113.6, 123.1, 124.7, 125.2, 127.0, 127.2, 127.4, 128.9, 129.2, 130.1, 130.3, 131.3, 131.6, 132.4, 133.4, 138.3, 138.6, 162.8, 164.5, 167.6, 171.8, 173.6;

(207) MS [ESI.sup.]: m/z (%): expected value: 660.29, experimental value: 659.2 [M-H].sup..

(208) The product of Embodiment 21 has a structure of formula (III-21):

(209) ##STR00038##

(210) The NMR spectroscopy of the product in Embodiment 21 is shown below:

(211) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.80-1.90 (br, 4H; CH.sub.2), 1.95-2.05 (q, J=8.6 Hz, 2H; CH.sub.2), 2.25-2.35 (t, J=7.3 Hz, 2H; CH.sub.2), 2.75-2.85 (m, 1H; CH.sub.2), 3.05-3.15 (m, 1H; CH.sub.2), 3.20-3.30 (br, 4H; CH.sub.2), 4.20-4.30 (q, J=9.4 Hz, 1H; CH), 4.50-4.60 (q, J=9.8 Hz, 1H; CH), 4.60-4.70 (s, 2H; CH.sub.2), 7.20-7.25 (m, 1H; CH), 7.25-7.35 (m, J=6.0 Hz, 4H; CH), 7.35 (d, J=8.1 Hz, 1H; NH), 7.85 (t, J=7.5 Hz, 1H; CH), 8.25 (d, J=7.5 Hz, 1H; NH), 8.4 (d, J=8.1 Hz, 1H; NH), 8.5 (t, J=7.2 Hz, 3H; CH);

(212) .sup.13C NMR (75 MHz, DMSO-d6): =24.3, 26.1, 26.8, 30.5, 37.8, 42.0, 42.5, 51.8, 54.2, 54.4, 115.2, 115.3, 122.8, 125.8, 126.2, 126.7, 128.5, 129.7, 131.1, 132.8, 138.2, 157.3, 163.3, 163.9, 167.2, 171.5, 173.5, 174.2;

(213) MS [ESI.sup.]: m/z (%): expected value: 614.65, experimental value: 613.10 [M-H].sup..

(214) Continuing in FIG. 7, which illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-21) at different pH values. In Experimental Examples 710, 720, 730, 740, 750, 760, 770 and 780, the water-soluble peptide fluorescence material of formula (III-21) is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 710 to 750, the water-soluble peptide fluorescence material is placed in environments having the pH value of 10 to 6. As shown in FIG. 7, Experimental Examples 710 to 750 have low fluorescence intensities, so no significant fluorescence marker is shown. While the pH value is decreased to 5 (Experimental Examples 760), the fluorescence intensity is significantly increased, and the emission peak is at about 550 nm to show the green fluorescence. The pH value is decreased to 4 in Experimental Examples 770, and the fluorescence intensity thereof is further increased. However, the fluorescence intensity of Experimental Examples 780 is decreased when the pH value is decreased from 4 to 3. Therefore, the water-soluble peptide fluorescence material of formula (III-21) has the highest fluorescence intensity at the pH value of 4.

(215) 2-3. Solid Phase Peptide Synthesis (Grafting Three Amino Acids)

(216) Embodiments of grafting three amino acids is begun with swelling 2-chlorotrityl chloride resin (1.2 g, 1 mmol) in anhydrous dichloromethane (CH.sub.2Cl.sub.2) for 30 min, and a first amino acid having a Fmoc protective group is dissolved in anhydrous DMF and DIEA (0.62 ml, 3.75 mmol). Then, the first amino acid is reacted with the 2-chlorotrityl chloride resin for 30 minutes to graft the first amino acid on the 2-chlorotrityl chloride resin. After that, piperidine (20% in DMF) is added and reacted for 20 minutes to remove the Fmoc protective group on the first amino acid, and the above step is repeated twice (2 minutes each time). Subsequently, a second amino acid having a Fmoc protective group, DIEA (0.6225 ml, 3.75 mmol) and HBTU (0.57 g, 1.5 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as a coupling agent to make the second amino acid couple to a free amino group (the Fmoc protective group thereon is removed) of the first amino acid.

(217) Then, piperidine (20% in DMF) is again added and reacted for 20 minutes, and the above step is repeated twice (2 minutes each time) to remove the Fmoc protective group on the second amino acid. Subsequently, a third amino acid having a Fmoc protective group, DIEA (0.6225 ml, 3.75 mmol) and HBTU (0.57 g, 1.5 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as the coupling agent to make the third amino acid couple to a free amino group (the Fmoc protective group thereon is removed) of the second amino acid.

(218) In order to remove the Fmoc protective group on the third amino acid, piperidine (20% in DMF) is added and reacted for 20 minutes, and the above step is repeated twice (2 minutes each time). After that, the terminal luminophore, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as the coupling agent to make the terminal luminophore couple to a free amino group (the Fmoc protective group thereon is removed) of the third amino acid.

(219) The reaction mixture is stirred overnight, and then the water-soluble peptide fluorescence material is cleaved from the 2-chlorotrityl chloride resin through treatment of trifluoroacetic acid (90% in deionized water) for 3 hours. The resulting solution is further dried under a stream of air, and diethyl ether is added to precipitate a target product. Then, the precipitate is dried under vacuum to remove residual solvent, and the remained solid product is the water-soluble peptide fluorescence material, which is under structure analysis by a nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR). Continuing in Table 3, which shows different water-soluble peptide fluorescence materials synthesized from three amino acids and various terminal luminophores.

(220) TABLE-US-00004 TABLE 4 Different water-soluble peptide fluorescence materials synthesized from three amino acids and various terminal luminophores. second structure first amino amino of the acid acid third amino terminal product (weight, (weight, acid luminophore (color, Embodiment mol) mol) (weight, mol) (weight, mol) weight) Embodiment Fmoc-L- Fmoc-L- Fmoc-L- PPNI III-22 22 aspartic aspartic phenylalanine (0.677 g, (orange acid acid (0.58 g, 2.0 mmol) solid, (0.62 g, (0.62 g, 1.5 mmol) 0.554 g) 1.5 mmol) 1.5 mmol) Embodiment Fmoc-L- Fmoc-L- Fmoc-L- PPNI III-23 23 glutamic aspartic phenylalanine (0.4365 g, (yellow acid acid (0.387 g, 1.0 mmol) solid, (0.425 g, (0.414 g, 1.0 mmol) 0.310 g) 1.0 mmol) 1.0 mmol)

(221) The product of Embodiment 22 has a structure of formula (III-22):

(222) ##STR00039##

(223) The NMR spectroscopy of the product in Embodiment 22 is shown below:

(224) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.85-1.95 (br, 4H; CH.sub.2), 2.60-3.10 (m, 6H; CH.sub.2), 3.20-3.30 (br, 4H; CH.sub.2), 4.50-4.60 (m, 2H; CH), 4.67 (s, 3H; CH.sub.2), 7.20-7.25 (m, 1H; CH), 7.25-7.35 (m, 4H; CH), 7.36 (d, J=8.1 Hz, 1H; CH), 7.85 (t, J=7.8 Hz, 1H; CH), 8.05 (d, J=8.1 Hz, 1H; NH), 8.41 (d, J=8.4 Hz, 1H; NH), 8.45-8.55 (m, 4H; CH);

(225) .sup.13C NMR (75 MHz, DMSO-d6): =23.9, 25.7, 35.9, 36.1, 37.6, 42.1, 48.6, 49.4, 53.9, 54.0, 114.8, 114.9, 122.4, 125.5, 125.8, 126.2, 128.0, 129.3, 130.7, 132.4, 137.8, 156.9, 162.8, 163.4, 166.8, 170.3, 171.1, 171.6, 171.7, 172.1, 181.0;

(226) MS [ESI.sup.]: m/z (%): expected value: 715.25, experimental value: 714.2 [M-H].sup..

(227) Continuing in FIG. 8, which illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-22) at different pH values. In Experimental Examples 810, 820, 830, 840, 850, 860, 870 and 880, the water-soluble peptide fluorescence material of formula (III-22) is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 810 to 850, the water-soluble peptide fluorescence material is respectively placed in environments having the pH value of 10 to 6. As shown in FIG. 8, Experimental Examples 810 to 850 have low fluorescence intensities, so no significant fluorescence marker is shown. While the pH value is decreased to 5 (Experimental Example 860), the fluorescence intensity is significantly increased, and the emission peak is at about 575 nm to show the yellow fluorescence.

(228) Then, the fluorescence intensity of Experimental Example 870 is decreased when decreasing the pH value from 5 to 4, and the fluorescence intensity of Experimental Example 870 (pH=3) is slightly increased. Therefore, the water-soluble peptide fluorescence material of formula (III-22) has the highest fluorescence intensity at the pH value of 5. In addition, the fluorescence intensity of Experimental Example 860 (pH=5) is 90 times of the fluorescence intensity of Experimental Example 810 (pH=1), which represents that the water-soluble peptide fluorescence material has obvious light-emitting interval and easily to identify and detect positions of the acidic cells.

(229) The product of Embodiment 23 has a structure of formula (III-23):

(230) ##STR00040##

(231) The NMR spectroscopy of the product in Embodiment 23 is shown below:

(232) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.80-1.90 (br, 4H; CH.sub.2), 1.95-2.05 (q, J=9.7 Hz, 2H; CH.sub.2), 2.25-2.35, (t, J=4.9 Hz, 2H; CH.sub.2), 2.65-2.75 (m, 3H; CH.sub.2), 2.95-3.15 (m, 1H, CH.sub.2), 3.20-3.30 (br, 4H, CH.sub.2), 4.15-4.25 (q, J=6.9 Hz, 1H; CH), 4.45-4.55 (q, J=12.1 Hz, 2H; CH), 4.60 (s, 3H; CH), 7.15-7.30 (m, 5H; CH), 7.30-7.40 (d, J=7.8 Hz, 1H; NH), 7.85 (t, J=8.1 Hz, 1H; CH), 7.95 (d, J=7.5 Hz, 1H; NH), 8.35 (d, J=8.1 Hz, 2H; CH), 8.45-8.55 (t, J=7.8 Hz, 3H; CH);

(233) .sup.13C NMR (75 MHz, DMSO-d6): =24.3, 26.1, 26.7, 36.1, 30.2, 36.4, 38.06, 42.4, 49.9, 51.7, 54.4, 115.2, 115.3, 122.8, 125.8, 126.2, 126.6, 128.4, 129.7, 132.4, 138.2, 157.3, 163.2, 163.8, 167.3, 170.9, 171.5, 172.0, 173.4, 174.2;

(234) MS [ESI.sup.]: m/z (%): expected value: 729.73, experimental value: 728.30 [M-H].sup..

(235) Continuing in FIG. 9, which illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-23) in co-solvents having different proportions of water and dimethyl sulfoxide. In Experimental Examples 901, 902, 903, 904, 905, 906, 907, 908, 909 and 910, water respectively has 0, 10, 20, 30, 40, 50, 60, 70, 80 and 90% of a total volume of the co-solvent. As shown in FIG. 9, the water-soluble peptide fluorescence material of formula (III-23) has the highest fluorescence intensity in Experimental Example 910 to provide a more obvious fluorescence marker.

(236) Given the above, the fluorescence intensity of the water-soluble peptide fluorescence material of formula (III-23) is increased corresponding to the increase of the volume ratio of water and has a phenomenon of aggregation-induced emission in water. In addition, the water-soluble peptide fluorescence material of formula (III-23) has the emission wavelength of about 550 nm, so the observed fluorescence has a color of green.

(237) FIG. 10 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-23) at different pH values. In Experimental Examples 1010, 1020, 1030, 1040, 1050, 1060, 1070 and 1080, the water-soluble peptide fluorescence material of formula (III-23) is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 1010 to 1050, the water-soluble peptide fluorescence material is respectively placed in environments having the pH value of 10 to 6. As shown in FIG. 10, Experimental Examples 1010 to 1050 have low fluorescence intensities, so no significant fluorescence marker is shown. While the pH value is decreased to 5 (Experimental Example 1060), the fluorescence intensity is significantly increased, and the emission peak is at about 525 nm to show the green fluorescence. Then, the pH value is decreased to 4 and 3, and the fluorescence intensities of Experimental Examples 1070 and 1080 are slightly increased. The water-soluble peptide fluorescence material not only provides obvious marker, but also achieves the same effect of the fluorescence at a low concentration, and thereby reduces the costs.

(238) 2-4. Solid Phase Peptide Synthesis (Grafting Four Amino Acids)

(239) Embodiments of grafting four amino acids is begun with swelling 2-chlorotrityl chloride resin (1.2 g, 1 mmol) in anhydrous dichloromethane (CH.sub.2Cl.sub.2) for 30 min, and a first amino acid having a Fmoc protective group is dissolved in anhydrous DMF and DIEA (0.83 ml, 5.0 mmol). Then, the first amino acid is reacted with the 2-chlorotrityl chloride resin for 1 hour to graft the first amino acid on the 2-chlorotrityl chloride resin. After that, piperidine (20% in DMF) is added and reacted for 20 minutes to remove the Fmoc protective group on the first amino acid, and the above step is repeated twice (2 minutes each time).

(240) Subsequently, a second amino acid having a Fmoc protective group, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin for 30 minutes. During the reaction, the HBTU acts as a coupling agent to make the second amino acid couple to a free amino group (the Fmoc protective group thereon is removed) of the first amino acid. Then, piperidine (20% in DMF) is again added and reacted for 20 minutes, and the above step is repeated twice (2 minutes each time) to remove the Fmoc protective group on the second amino acid.

(241) Subsequently, a third amino acid having a Fmoc protective group, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin for 30 minutes. During the reaction, the HBTU acts as the coupling agent to make the third amino acid couple to a free amino group (the Fmoc protective group thereon is removed) of the second amino acid. In order to remove the Fmoc protective group on the third amino acid, piperidine (20% in DMF) is added and reacted for 20 minutes, and the above step is repeated twice (2 minutes each time).

(242) Then, a fourth amino acid having a Fmoc protective group, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin for 30 minutes. During the reaction, the HBTU acts as the coupling agent to make the fourth amino acid couple to a free amino group (the Fmoc protective group thereon is removed) of the third amino acid. As the same step mentioned above, the Fmoc protective group on the fourth amino acid is removed by adding piperidine (20% in DMF) to react for 20 minutes, and the above step is repeated twice (2 minutes each time).

(243) After that, the terminal luminophore, DIEA (0.83 ml, 5.0 mmol) and HBTU (0.76 g, 2.0 mmol) are dissolved in anhydrous DMF and reacted with the 2-chlorotrityl chloride resin. During the reaction, the HBTU acts as the coupling agent to make the terminal luminophore couple to a free amino group (the Fmoc protective group thereon is removed) of the fourth amino acid.

(244) The reaction mixture is stirred overnight, and then the water-soluble peptide fluorescence material is cleaved from the 2-chlorotrityl chloride resin through treatment of trifluoroacetic acid (90% in deionized water) for 3 hours. The resulting solution is further dried under a stream of air, and diethyl ether is added to precipitate a target product. Then, the precipitate is dried under vacuum to remove residual solvent, and the remained solid product is the water-soluble peptide fluorescence material, which is under structure analysis by a nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR). Continuing in Table 5, which shows different water-soluble peptide fluorescence materials synthesized from four amino acids and various terminal luminophores.

(245) TABLE-US-00005 TABLE 5 Different water-soluble peptide fluorescence materials synthesized from four amino acids and various terminal luminophores. first second third fourth terminal structure of Embodi- amino acid amino acid amino acid amino acid luminophore the product ment (weight, mol) (weight, mol) (weight, mol) (weight, mol) (weight, mol) (color, weight) Embodi- Fmoc-O-tert-butyl- Fmoc-L-glycine Fmoc-L-glycine Fmoc-L-glycine NI III-24 ment 24 L-tyrosine (0.6 g, (0.6 g, (0.6 g, (0.77 g, (white solid, (0.92 g, 2.0 mmol) 2.0 mmol) 2.0 mmol) 3.0 mmol) 0.42 g) 2.0 mmol) Embodi- Fmoc-O-tert-butyl- Fmoc-L-glycine Fmoc-Pbf-L-arginine Fmoc-L-phenylalanine NI III-25 ment 25 L-aspartic acid (0.6 g, (1.3 g, (0.78 g, (0.51 g, (white solid, (0.92 g, 2.0 mmol) 2.0 mmol) 2.0 mmol) 2.0 mmol) 0.29 g) 2.0 mmol) Embodi- Fmoc-L-aspartic Fmoc-L-aspartic Fmoc-L-aspartic Fmoc-L-phenylalanine PPNI III-26 ment 26 acid acid acid (0.58 g, (0.677 g, (brown solid, (0.62 g, (0.62 g, (0.62 g, 1.5 mmol) 2.0 mmol) 0.734 g) 1.5 mmol) 1.5 mmol) 1.5 mmol) Embodi- Fmoc-L-glutamic Fmoc-L-glutamic Fmoc-L-glutamic Fmoc-L-phenylalanine PPNI III-27 ment 27 acid acid acid (0.387 g, (0.4365 g, (yellow solid, (0.425 g, (0.425 g, (0.425 g, 1.0 mmol) 1.0 mmol) 0.350 g) 1.0 mmol) 1.0 mmol) 1.0 mmol)

(246) The product of Embodiment 24 has a structure of formula including a peptide sequence Gly-Gly-Gly-Tyr (SEQ ID NO: 1) (111-24):

(247) ##STR00041##

(248) The NMR spectroscopy of the product in Embodiment 24 is shown below:

(249) .sup.1H NMR (300 MHz, DMSO-d6): =2.75-2.85 (m, 1H; CH.sub.2), 2.90-3.00 (m, 1H; CH.sub.2), 3.65-3.90 (m, 6H; CH.sub.2), 4.30-4.45 (m, 1H; CH), 4.781 (s, 2H; CH.sub.2), 6.69 (d, J=8.9 Hz, 2H; CH), 7.04 (d, J=8.1 Hz, 2H; CH), 7.91 (t, J=7.65 Hz, 2H; CH), 8.05-8.20 (m, 2H; NH), 8.20-8.30 (m, 1H; NH), 8.45-8.60 (m, 5H; CH, NH);

(250) .sup.13C NMR (75 MHz, DMSO-d6): =37.1, 42.6, 42.9, 43.0, 43.3, 54.9, 116.0, 122.9, 128.2, 128.4, 131.0, 131.8, 132.3, 135.5, 156.9, 164.3, 168.2, 169.3, 169.9, 170.0, 173.9;

(251) MS [ESI.sup.]: m/z (%): expected value: 589.18, experimental value: 588.2 [M-H].sup..

(252) The product of Embodiment 25 has a structure of formula including a peptide sequence Phe-Arg-Gly-Asp (SEQ ID NO: 2) (111-25):

(253) ##STR00042##

(254) The NMR spectroscopy of the product in Embodiment 25 is shown below:

(255) .sup.1H NMR (300 MHz, DMSO-d6): =1.45-1.70 (m, 3H; CH.sub.2), 1.70-1.85 (m, 1H; CH.sub.2), 2.60-2.70 (m, 2H; CH.sub.2), 2.80-2.95 (m, 1H; CH.sub.2), 3.00-3.20 (m, 3H; CH.sub.2), 3.65-3.90 (m, 2H; CH.sub.2), 4.25-4.40 (m, 1H; CH), 4.45-4.65 (m, 1H; CH), 4.706 (s, 2H; CH.sub.2), 7.20-7.35 (m, 5H; CH), 7.91 (t, J=7.65 Hz, 2H; CH), 8.10-8.20 (m, 1H; NH), 8.20-8.30 (m, 1H; NH), 8.45-8.60 (m, 5H; CH, NH);

(256) .sup.13C NMR (75 MHz, DMSO-d6): =25.8, 30.2, 37.5, 38.3, 42.7, 43.2, 49.6, 53.3, 55.0, 122.8, 127.2, 128.2, 128.4, 129.0, 130.3, 131.8, 132.3, 135.5, 138.6, 157.7, 164.2, 167.6, 169.4, 172.0, 172.4, 172.9, 173.4;

(257) MS [ESI.sup.]: m/z (%): expected value: 730.27, experimental value: 731.3 [M-H].sup..

(258) The product of Embodiment 26 has a structure of formula including a peptide sequence Phe-Asp-Asp-Asp (SEQ ID NO: 3) (111-26):

(259) ##STR00043##

(260) The NMR spectroscopy of the product in Embodiment 26 is shown below:

(261) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.80-1.90 (br, 4H; CH.sub.2), 2.55-2.90 (m, 7H; CH.sub.2), 3.00-3.10 (m, 1H; CH.sub.2), 3.20-3.30 (br, 4H; CH.sub.2), 4.55-4.65 (m, 4H; CH), 4.67 (s, 2H; CH.sub.2), 7.20-7.25 (m, 1H; CH), 7.25-7.35 (m, 4H; CH), 7.36 (d, J=8.4 Hz, 1H; NH), 7.85 (t, J=7.95 Hz, 1H, NH), 7.99 (d, J=8.1 Hz, 1H; NH), 8.14 (d, J=8.1 Hz, 1H; NH), 8.35-8.55 (m, 5H; CH);

(262) .sup.13C NMR (75 MHz, DMSO-d6): =23.9, 25.8, 36.0, 36.1, 36.2, 37.7, 42.2, 48.7, 49.4, 49.7, 53.9, 54.1, 114.8, 115.0, 122.4, 125.5, 125.9, 126.3, 128.1, 129.40, 129.44, 130.8, 132.5, 137.8, 157.0, 158.2, 158.7, 162.9, 163.5, 166.9, 170.3, 170.5, 171.2, 171.8, 171.9, 172.2;

(263) MS [ESI.sup.]: m/z (%): expected value: 830.28, experimental value: 829.2 [M-H].sup..

(264) The product of Embodiment 27 has a structure of formula including a peptide sequence Phe-Glu-Glu-Glu (SEQ ID NO: 4) (111-27):

(265) ##STR00044##

(266) The NMR spectroscopy of the product in Embodiment 27 is shown below:

(267) .sup.1H NMR (300 MHz, DMSO-d6): =1.65-1.75 (br, 2H; CH.sub.2), 1.80-1.90 (br, 4H; CH.sub.2), 1.90-2.05 (q, J=9.0 Hz, 5H; CH.sub.2), 2.25-2.35 (t, J=8.1 Hz, 7H; CH.sub.2), 2.75-2.85 (m, 1H; CH.sub.2), 3.00-3.10 (m, 1H; CH.sub.2), 3.20-3.30 (br, 4H; CH.sub.2), 4.20-4.30 (q, J=7.7 Hz, 1H; CH), 4.30-4.40 (q, J=10.8 Hz, 2H; CH), 4.55-4.65 (m, 1H; CH), 4.65 (s, 2H; CH.sub.2), 7.20-7.25 (m, 1H; CH), 7.25-7.30 (m, 4H; CH), 7.35 (d, J=8.1 Hz, 1H; NH), 7.85 (t, J=7.95 Hz, 1H, CH), 8.00 (d, J=7.2 Hz, 1H; NH), 8.20 (d, J=7.8 Hz, 2H; NH), 8.4-8.55 (m, 4H; CH);

(268) .sup.13C NMR (75 MHz, DMSO-d6): =24.5, 26.4, 26.8, 28.0, 28.2, 30.6, 30.7, 30.8, 38.0, 42.7, 51.9, 52.3, 52.6, 54.5, 54.6, 115.5, 115.6, 123.1, 126.1, 126.5, 126.9, 128.7, 129.9, 131.4, 133.1, 138.4, 157.6, 163.5, 164.1, 167.5, 171.5, 171.6, 171.8;

(269) MS [ESI.sup.]: m/z (%): expected value: 872.87, experimental value: 871.2 [M-H].sup..

(270) FIG. 11 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-27) at different pH values. In Experimental Examples 1110, 1120, 1130, 1140, 1150, 1160, 1170 and 1180, the water-soluble peptide fluorescence material of formula (III-27) is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 1110 to 1150, the water-soluble peptide fluorescence material is respectively placed in environments having the pH value of 10 to 6. As shown in FIG. 11, Experimental Examples 1110 to 1150 have low fluorescence intensities, so no significant fluorescence marker is shown. While the pH value is decreased to 5 (Experimental Example 1160), the fluorescence intensity is significantly increased, and the emission peak is at about 525 nm to show the green fluorescence. Then, the pH value is decreased to 4 and 3, and the fluorescence intensities of Experimental Examples 1170 and 1180 are significantly increased. The water-soluble peptide fluorescence material not only provides obvious marker, but also achieves the same effect of the fluorescence at a low concentration, and thereby reduces the costs.

(271) 2-5. Solid Phase Peptide Synthesis (Grafting Five Amino Acids)

(272) Refer to embodiments of grafting four amino acids mentioned in 2-4 to understand embodiments of grafting five amino acids. Before grafting the terminal luminophore, a step of grafting a fifth amino acid is performed in a way the same as grafting the fourth amino acid, and the details are not described herein. The product is also under structure analysis by a nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR). Continuing in Table 6, which shows different water-soluble peptide fluorescence materials synthesized from five amino acids and various terminal luminophores.

(273) TABLE-US-00006 TABLE 6 Different water-soluble peptide fluorescence materials synthesized from five amino acids and various terminal luminophores. first second third fourth fifth terminal structure of Embodi- amino acid amino acid amino acid amino acid amino acid luminophore the product ment (weight, mol) (weight, mol) (weight, mol) (weight, mol) (weight, mol) (weight, mol) (color, weight) Embodi- Fmoc-L-alanine Fmoc-L-glutamic Fmoc-L-glycine Fmoc-L-aspartic Fmoc-L-phenylalanine NI III-28 ment 28 (0.623 g, acid (0.6 g, acid (0.78 g, (0.77 g, (white solid, 2.0 mmol) (0.851 g, 2.0 mmol) (0.823 g, 2.0 mmol) 3.0 mmol) 0.05 g) 2.0 mmol) 2.0 mmol) Embodi- Fmoc-L-alanine Fmoc-L-glutamic Fmoc-L-glycine Fmoc-L-aspartic Fmoc-L-phenylalanine PPNI III-29 ment 29 (0.623 g, acid (0.6 g, acid (0.78 g, (1.02 g, (yellow solid, 2.0 mmol) (0.851 g, 2.0 mmol) (0.823 g, 2.0 mmol) 3.0 mmol) 0.6956 g) 2.0 mmol) 2.0 mmol)

(274) The product of Embodiment 28 has a structure of formula including a peptide sequence Phe-Asp-Gly-Glu-Ala (SEQ ID NO: 5) (111-28):

(275) ##STR00045##

(276) The NMR spectroscopy of the product in Embodiment 28 is shown below:

(277) .sup.1H NMR (300 MHz, DMSO-d6): =1.29 (d, J (H, H)=7.2 Hz, 3H; CH3), 1.70-1.90 (m, 1H; CH.sub.2), 1.85-2.05 (m, 1H; CH.sub.2), 2.29 (t, J (H, H)=8.25 Hz, 2H; CH.sub.2), 2.70-2.90 (m, 2H; CH.sub.2), 3.00-3.15 (m, 1H; CH.sub.2), 3.65-3.85 (m, 2H; CH.sub.2), 4.15-4.30 (m, 1H; CH), 4.30-4.40 (m, 1H; CH), 4.50-4.65 (m, 2H; CH), 4.78 (s, 2H; CH.sub.2), 7.20-7.30 (m, 5H; CH), 7.93 (t, J (H, H)=7.8 Hz, 4H; CH), 8.29 (d, J (H, H)=7.2 Hz, 1H; NH), 8.40-8.65 (m, 6H; NH, CH);

(278) .sup.13C NMR (75 MHz, DMSO-d6): =17.8, 28.5, 30.9, 36.9, 38.4, 43.1, 48.4, 50.6, 52.4, 54.9, 122.8, 127.2, 128.2, 128.4, 129.0, 130.2, 131.8, 132.3, 135.5, 138.5, 164.2, 167.6, 169.2, 171.6, 171.7, 172.0, 172.7, 174.8, 175.0;

(279) MS [ESI.sup.]: m/z (%): expected value: 774.25, experimental value: 773.3 [M-H].sup..

(280) FIG. 12 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-28) in co-solvents having different proportions of water and dimethyl sulfoxide. In Experimental Example 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210 and 1211, water respectively has 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 99% of a total volume of the co-solvent. As shown in FIG. 12, the water-soluble peptide fluorescence material of formula (III-28) has low fluorescence intensity in co-solvents of Experimental Examples 1201 to 1209. As such, no significant fluorescence marker is shown, so it is difficult to observe apparent fluorescence visually. While a volume ratio of water is increased to 90% (Experimental Example 1210), the fluorescence intensity is significantly increased to 150 fluorescent units. The volume ratio of water is further increased to 99%, and the fluorescence intensity of Experimental Example 1211 is sharply increased to about 110 fluorescent units, so as to provide a more obvious fluorescence marker. Given the above, the fluorescence intensity of the water-soluble peptide fluorescence material of formula (III-28) is increased corresponding to the increase of the volume ratio of water and has a phenomenon of aggregation-induced emission in water. In addition, the water-soluble peptide fluorescence material of formula (III-28) has the emission wavelength of about 400 nm, so the observed fluorescence has a color of violet. FIG. 13 depicts a ratio of the fluorescence intensity between Experimental Examples 1202 to 1211 and Experimental Example 1201, at the emission wavelength of 400 nm. As shown in FIG. 13, the fluorescence intensity of Experimental Example 1211 is 225 times of the fluorescence intensity of Experimental Example 1201.

(281) FIG. 14 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-28) at different pH values. In Experimental Examples 1410, 1420, 1430, 1440, 1450, 1460, 1470 and 1480, the water-soluble peptide fluorescence material of formula (III-28) is respectively placed in environments having a pH value of 10, 9, 8, 7, 6, 5, 4 and 3 for testing. In Experimental Examples 1410 to 1450, the water-soluble peptide fluorescence material is respectively placed in environments having the pH value of 10 to 6. As shown in FIG. 14, Experimental Examples 1410 to 1450 have low fluorescence intensities, so no significant fluorescence marker is shown. While the pH value is decreased to 5 (Experimental Example 1460), the fluorescence intensity is significantly increased, and the emission peak is at about 400 nm to show the purple fluorescence. Then, the pH value is decreased to 4 and 3, and the fluorescence intensities of Experimental Examples 1470 and 1480 are significantly increased. The water-soluble peptide fluorescence material not only provides obvious marker, but also achieves the same effect of the fluorescence at a low concentration, and thereby reduces the costs.

(282) The product of Embodiment 29 has a structure of formula including a peptide sequence Phe-Asp-Gly-Glu-Ala (SEQ ID NO: 6) (111-29):

(283) ##STR00046##

(284) The NMR spectroscopy of the product in Embodiment 29 is shown below:

(285) .sup.1H NMR (300 MHz, DMSO-d6): =1.30 (d, J (H, H)=7.2 Hz, 3H; CH.sub.3), 1.71 (br, 2H; CH.sub.2), 1.75-1.85 (m, 1H; CH.sub.2), 2.27 (br, 4H; CH.sub.2), 1.90-2.05 (m, 1H; CH.sub.2), 2.30 (t, J (H, H)=8.1 Hz, 2H; CH.sub.2), 2.55-2.65 (m, 1H; CH.sub.2), 2.70-2.95 (m, 2H; CH.sub.2), 3.00-3.15 (m, 1H; CH.sub.2), 3.25 (br, 4H; CH.sub.2), 3.65-3.85 (m, 2H; CH.sub.2), 4.10-4.25 (m, 1H; CH), 4.30-4.40 (m, 1H; CH), 4.50-4.65 (m, 2H; CH), 4.69 (s, 2H; CH.sub.2), 7.20-7.30 (m, 5H; CH), 7.35 (d, J (H, H)=8.4 Hz, 1H; NH), 7.80-8.00 (m, 3H; CH), 8.29 (d, J (H, H)=7.2 Hz, 1H; NH), 8.35-8.60 (m, 5H; NH, CH);

(286) .sup.13C NMR (75 MHz, DMSO-d6): =17.8, 24.8, 26.6, 28.5, 30.9, 36.8, 38.4, 43.0, 43.2, 48.4, 50.6, 52.3, 54.9, 115.7, 115.9, 123.3, 126.4, 126.8, 127.2, 129.0, 130.2, 131.4, 131.7, 133.4, 138.5, 157.8, 163.8, 164.4, 167.8, 169.2, 171.6, 171.7, 172.0, 172.7, 174.8, 175.0;

(287) MS [ESI.sup.]: m/z (%): expected value: 857.32, experimental value: 856.60 [M-H].sup..

(288) 2-6. Solid Phase Peptide Synthesis (Grafting Six Amino Acids)

(289) Refer to embodiments of grafting four amino acids mentioned in 2-4 to understand embodiments of grafting six amino acids. Before grafting the terminal luminophore, a step of grafting a fifth amino acid and a sixth amino acid is performed in a way the same as grafting the fourth amino acid, and the details are not described herein. The product is also under structure analysis by a nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR). Continuing in Table 7, which shows different water-soluble peptide fluorescence materials synthesized from five amino acids and various terminal luminophores.

(290) TABLE-US-00007 TABLE 7 Different water-soluble peptide fluorescence materials synthesized from six amino acids and various terminal luminophores first second third fourth fifth sixth terminal structure of Embodi- amino acid amino acid amino acid amino acid amino acid amino acid luminophore the product ment (weight, mol) (weight, mol) (weight, mol) (weight, mol) (weight, mol) (weight, mol) (weight, mol) (color, weight) Embodi- Fmoc-O-tert- Fmoc-L- Fmoc-L- Fmoc-L- Fmoc-L- Fmoc-L- NI III-30 ment 30 butyl-L- glycine glycine glycine glycine glycine (0.51 g, (white solid, tyrosine (0.6 g, (0.6 g, (0.6 g, (0.6 g, (0.6 g, 2.0 mmol) 0.20 g) (0.92 g, 2.0 mmol) 2.0 mmol) 2.0 mmol) 2.0 mmol) 2.0 mmol) 2.0 mmol) Embodi- Fmoc-L-valine Fmoc-L- Fmoc-L-valine Fmoc-L-lysine Fmoc-L-isolucine Fmoc-L- NI III-31 ment 31 (0.68 g, alanine (0.68 g, (0.94 g, (0.71 g, phenylalanine (0.79 g, (white solid, 2.0 mmol) (0.622 g, 2.0 mmol) 2.0 mmol) 2.0 mmol) (0.78 g, 3.0 mmol) 0.92 g) 2.0 mmol) 2.0 mmol)

(291) The product of Embodiment 30 has a structure of formula including a peptide sequence Gly-Gly-Gly-Gly-Gly-Tyr (SEQ ID NO: 7) (111-30):

(292) ##STR00047##

(293) The NMR spectroscopy of the product in Embodiment 30 is shown below:

(294) .sup.1H NMR (300 MHz, DMSO-d6): =2.70-3.05 (m, 2H; CH.sub.2), 3.60-3.90 (m, 10H; CH.sub.2), 4.30-4.40 (m, 1H; CH), 4.70-4.80 (m, 2H; CH.sub.2), 6.68 (d, J=8.4 Hz, 2H; CH), 7.03 (d, J=8.4 Hz, 2H; CH), 7.94 (t, J=7.8 Hz, 2H; CH), 8.00-8.10 (m, 2H; NH), 8.10-8.25 (m, 3H; NH), 8.50-8.65 (m, 4H; CH);

(295) .sup.13C NMR (75 MHz, DMSO-d6): =37.0, 42.2, 42.5, 43.0, 43.3, 54.8, 116.0, 122.9, 128.2, 128.3, 128.4, 128.5, 131.0, 131.8, 135.5, 156.9, 164.3, 168.2, 169.5, 169.9, 170.07, 170.13, 170.3, 173.9;

(296) MS [ESI.sup.]: m/z (%): expected value: 703.22, experimental value: 702.0[M-H].sup..

(297) FIG. 15 illustrates a fluorescence intensity and an emission wavelength of the water-soluble peptide fluorescence material of formula (III-30) in co-solvents having different proportions of water and dimethyl sulfoxide. In Experimental Example 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510 and 1511, water respectively has 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100% of a total volume of the co-solvent. As shown in FIG. 15, the water-soluble peptide fluorescence material of formula (III-30) has low fluorescence intensity (lower than 100 fluorescent units) in co-solvents of Experimental Examples 1501 to 1509. As such, no significant fluorescence marker is shown, so it is difficult to observe apparent fluorescence visually. While a volume ratio of water is increased to 90% (Experimental Example 1510), the fluorescence intensity is significantly increased to 200 fluorescent units. The volume ratio of water is further increased to 99%, and the fluorescence intensity of Experimental Example 1511 is sharply increased to about 700 fluorescent units, so as to provide a more obvious fluorescence marker. Accordingly, the fluorescence intensity of the water-soluble peptide fluorescence material of formula (III-30) is increased corresponding to the increase of the volume ratio of water and has a phenomenon of aggregation-induced emission in water. In addition, the water-soluble peptide fluorescence material of formula (III-30) has the emission wavelength of about 400 to 425 nm, so the observed fluorescence has a color of blue violet. FIG. 16 depicts a ratio of the fluorescence intensity between Experimental Examples 1502 to 1511 and Experimental Example 1501, at the emission wavelength of 410 nm. As shown in FIG. 16, the fluorescence intensity of Experimental Example 1511 is 100 times of the fluorescence intensity of Experimental Example 1501.

(298) The product of Embodiment 31 has a structure of formula including a peptide sequence Phe-Ile-Lys-Val-Ala-Val (SEQ ID NO: 8) (111-31):

(299) ##STR00048##

(300) The NMR spectroscopy of the product in Embodiment 31 is shown below:

(301) .sup.1H NMR (300 MHz, DMSO) : 0.75-1.00 (m, 18H), 1.05-1.15 (m, 1H), 1.23 (d, J=7.2, 3H), 1.30-1.40, 1.40-1.60, 1.60-1.80 (m, 2H, 4H, 2H), 1.90-2.15 (m, 2H), 2.70-2.90 (m, 3H), 3.00-3.10 (m, 1H), 4.10-4.30 (m, 3H), 4.30-4.50 (m, 2H), 4.55-4.70 (m, 3H), 7.20-7.35 (m, 5H), 7.60-7.85 (m, 4H), 7.85-8.00 (m, 4H), 8.00-8.15 (m, 2H), 8.45-8.60 (m, 5H);

(302) .sup.13C NMR (75 MHz, DMSO) =12.1, 16.1, 16.3, 18.8, 19.1, 20.0, 20.1, 23.2, 25.2, 27.6, 30.9, 31.7, 32.2, 37.7, 38.1, 43.2, 44.7, 48.8, 53.2, 54.7, 58.0, 58.2, 65.9, 122.9, 127.2, 128.2, 128.4, 129.0, 130.3, 131.8, 132.3, 135.5, 138.7, 164.2, 167.6, 171.3, 171.6, 171.7, 172.2, 173.2, 173.8;

(303) MS [ESI.sup.]: m/z (%): expected value: 912.47, experimental value: 913.5[M-H].sup..

(304) Given the above, the conjugated polymer of the present disclosure includes side chains of a tertiary amine group or a quaternary ammonium salt group. When the conjugated polymer of the present disclosure includes the side chains of the tertiary amine group, the conjugated polymer has a good hole-transporting property and water/alcohol solubility. Hence, when fabricating a layered structure, problems of mutual dissolution between different layers can be prevented due to the immiscibility between water/alcohol and the organic solvent for materials in other layers. This conjugated polymer can be used as hole-transporting material. Moreover, since this kind of the conjugated polymer has a good hole-transporting property, it can also be used as a solid electrolyte. When the conjugated polymer of the present disclosure includes the side chains of the quaternary ammonium salt group, the conjugated polymer can be doped to have a good conductive property, and can be used as a conductive polymer. Besides, the conjugated polymer with the quaternary ammonium salt group can be used for the modification of ITO to reduce the work function of the ITO.

(305) The embodiments of the present disclosure discussed above have various advantages, which are summarized below. The water-soluble peptide fluorescence material has a characteristic of aggregation-induced emission (AlE) by changing a nitrogen heterocycle on naphthalimide, so as to generate fluorescence of different colors. In addition, an amino acid sequence of the water-soluble peptide fluorescence material could be changed to develop color in acid, neutral or weak base environment. Furthermore, hydrogen bonds of the amino acid make the water-soluble peptide fluorescence material have characteristic of aggregation-induced emission in water, and the water-soluble peptide fluorescence material is able to form a film at room temperature, so additional initiator or heating process are not necessary. Summarize above points, the water-soluble peptide fluorescence material of the present disclosure has advantages of excellent image recognition, low toxicity to cells and low costs, and thus could generally acts as a fluorescence probe in application of cell image, organelle image, pharmaceutical carrier image and cancer cell detection.

(306) Although the present disclosure has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein. It will be apparent to those skilled in the art that various modifications and variations can be made to the structure of the present disclosure without departing from the scope or spirit of the disclosure. In view of the foregoing, it is intended that the present disclosure cover modifications and variations of this disclosure provided they fall within the scope of the following claims.